Taking Gene Silencing to the DNA Level
At Oncogenuity, our extensive research shows that ONCOlogues have promising potential for treating a broad range of clinical conditions with substantial unmet need thanks to their ability to target a wide variety of mutations with potentially limited side effects.
We have established proof-of-concept in a pre-clinical setting for various cancers. Our lead product candidate targets the KRAS G12D mutation, which plays a key role in many cancer types and was previously considered undruggable. We are also engaged in discovery work to validate ONCOlogues’ potential in treating genetic disorders and viruses, including COVID-19.